NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued on Friday. The brokerage set a “hold” rating on the stock.

NovaBay Pharmaceuticals Stock Up 4.7 %

NBY opened at $0.75 on Friday. NovaBay Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $12.84. The company has a 50-day simple moving average of $0.59 and a 200 day simple moving average of $1.75.

NovaBay Pharmaceuticals (NYSE:NBY) last issued its earnings results on Tuesday, August 13th. The company reported ($1.37) EPS for the quarter. The business had revenue of $2.40 million for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 744.33% and a negative net margin of 91.86%. Sell-side analysts anticipate that NovaBay Pharmaceuticals will post -1.41 EPS for the current year.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.